Autologous mRNA-modified Anti-cMET CAR-T Cells

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous, genetically-engineered T-lymphocytes that have been electroporated with an mRNA encoding a chimeric antigen receptor (CAR) consisting of an anti-human hepatocyte growth factor receptor (HGFR or cMET) single chain variable fragment (scFv), with potential antineoplastic activities. Upon administration, autologous mRNA-modified anti-cMET CAR-T cells direct T-cells to cMET-expressing tumor cells, which induces selective toxicity against cMET-expressing tumor cells and causes tumor cell lysis. cMET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays a key role in cancer cell growth, survival, angiogenesis, invasion, and metastasis.

**Synonyms:** - Autologous cMET Redirected CAR-T Cells - Autologous mRNA CART-cMET - cMET CAR-mRNA-electroporated Autologous T lymphocytes